BioMarin Pharmaceutical
BMRNNASDAQEnzyme replacement and gene therapy
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from
Key figures from SEC filings
Upcoming catalysts
Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.
No upcoming catalyst for BioMarin Pharmaceutical has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Voxzogo | Achondroplasia | Approved | Not disclosed | ▼ |
| Roctavian | Hemophilia A | Approved | Not disclosed | ▼ |
| BMN 349 | Complement-mediated diseases | Phase 1 | Not disclosed | ▼ |
What does BioMarin Pharmaceutical do?
BioMarin is a well-established rare disease company that has successfully transitioned to commercial profitability. Their flagship product Voxzogo treats achondroplasia with strong uptake worldwide. Their gene therapy Roctavian for hemophilia A received FDA approval but adoption has been slower than expected. The company generates meaningful revenue and is cash flow positive. For investors BMRN represents a lower-risk biotech with real revenue growth though the stock price reflects much of the near-term opportunity. Key questions are whether Voxzogo reaches peak sales and whether Roctavian adoption accelerates.
What to watch
Quarterly Voxzogo revenue growth trajectory
Roctavian treatment center expansion and uptake
BMN 349 Phase 1 safety and PK data
Competitive readouts from Ascendis Pharma
Operating margin expansion as products mature
Investment thesis
Moderate RiskBull case
BioMarin has transformed into a profitable rare disease leader with Voxzogo on a strong growth trajectory and peak sales estimates of $2-3B globally. Deep expertise in rare diseases with multiple approved products generating recurring revenue. Pipeline expanding beyond enzyme replacement into gene therapy and small molecules. Strong cash flow with no near-term dilution risk offers rare disease growth with commercial-stage stability.
Bear case
Roctavian uptake disappointing and may never reach peak sales estimates. Voxzogo faces potential competition from Ascendis Pharma TransCon CNP. Rare disease market inherently limited in size. Gene therapy manufacturing remains complex and expensive. Pipeline complement diversification is very early stage with high clinical risk.
Risk factors
Roctavian commercial adoption below expectations
Voxzogo competitive threats from next-gen therapies
Gene therapy manufacturing complexity
Rare disease market size limitations
Regulatory risk for gene therapy label expansions
Comparable companies
Sponsored
Get premium BMRN analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you